Form 4: Progyny Director Acquires Shares and Options

Progyny, Inc. Director Jeffrey G. Park acquired 7,924 shares of common stock and was granted stock options for 36,663 shares.

Summary

• Director Jeffrey G. Park acquired 7,924 shares of Progyny, Inc. common stock on May 21, 2026.
• These shares were acquired as part of Restricted Stock Units (RSUs) with a value of $0 per share at the time of acquisition.
• Mr. Park also received stock options to purchase 5,205 shares at an exercise price of $24.69 and another 31,458 shares at an exercise price of $24.69.
• The RSUs and options are subject to vesting conditions, generally tied to continued service and specific meeting dates, with a target vesting date of May 21, 2027.
• Following these transactions, Mr. Park beneficially owns 39,981 shares of common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents routine insider compensation and equity grants rather than a significant strategic shift or financial performance indicator.

Positives

• Director acquisition of shares and options can signal confidence in the company's future prospects.
• The grant of stock options aligns the director's interests with those of shareholders through potential equity appreciation.

Negatives

• The acquisition of 7,924 shares was through RSUs with a reported acquisition price of $0, indicating these were likely granted as compensation rather than purchased on the open market.
• The stock options have an exercise price of $24.69, meaning they will only be profitable if the stock price rises significantly above this level.

Risks

• Vesting of RSUs and stock options is contingent upon continued service, meaning forfeiture is possible if the director leaves the company before the vesting date.
• The value of the stock options is directly tied to the future stock performance of Progyny, Inc., which is subject to market volatility and company-specific risks.

Future Outlook

The future outlook for the acquired RSUs and stock options is dependent on Progyny, Inc.'s stock performance and the director's continued service, with vesting expected by May 21, 2027, or the day before the company's first annual meeting after the grant date.

Industry Context

StockSavvy.ai notes that insider transactions, such as this Form 4 filing by a Progyny director, are common in the employee benefits and compensation space within the health technology sector. These filings provide transparency into how executives and directors are compensated and their personal investment in the company.

Related Party Transactions

• The grant of stock options was issued to the Reporting Person in lieu of an annual cash retainer for board and committee service, representing a form of compensation.

Stakeholder Impact

• Shareholders: The acquisition of shares and options by a director can be seen as a positive signal of commitment, but the dilutive effect of options should be considered.
• Employees: This filing is part of standard corporate practice and does not directly impact most employees.
• Management: Reinforces standard compensation practices for directors.

Next Steps

• Monitor the vesting of RSUs and stock options based on continued service and company milestones.
• Observe future stock performance relative to the option exercise price.

Key Dates

Keywords

Progyny, PGNY, Form 4, SEC Filing, Insider Trading, Stock Options, Restricted Stock Units, Director, Beneficial Ownership, Equity Compensation